Terms: = Prostate cancer AND PBRM1, BAF180, 55193, PB1, MGC156156, MGC156155
15 results:
1. Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.
He T; Cheng C; Qiao Y; Cho H; Young E; Mannan R; Mahapatra S; Miner SJ; Zheng Y; Kim N; Zeng VZ; Wisniewski JP; Hou S; Jackson B; Cao X; Su F; Wang R; Chang Y; Kuila B; Mukherjee S; Dukare S; Aithal KB; D S S; Abbineni C; Vaishampayan U; Lyssiotis CA; Parolia A; Xiao L; Chinnaiyan AM
Proc Natl Acad Sci U S A; 2024 Apr; 121(15):e2322563121. PubMed ID: 38557192
[TBL] [Abstract] [Full Text] [Related]
2. Exploration of
Wang B; Deng Y; Xu Q; Gao J; Shen H; He X; Ding Q; Wang F; Guo H
Clin Radiol; 2023 May; 78(5):e417-e424. PubMed ID: 36805287
[TBL] [Abstract] [Full Text] [Related]
3. Selective and Cell-Active pbrm1 Bromodomain Inhibitors Discovered through NMR Fragment Screening.
Shishodia S; Nuñez R; Strohmier BP; Bursch KL; Goetz CJ; Olp MD; Jensen DR; Fenske TG; Ordonez-Rubiano SC; Blau ME; Roach MK; Peterson FC; Volkman BF; Dykhuizen EC; Smith BC
J Med Chem; 2022 Oct; 65(20):13714-13735. PubMed ID: 36227159
[TBL] [Abstract] [Full Text] [Related]
4. MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer.
Hagiwara M; Fushimi A; Bhattacharya A; Yamashita N; Morimoto Y; Oya M; Withers HG; Hu Q; Liu T; Liu S; Wong KK; Long MD; Kufe D
Oncoimmunology; 2022; 11(1):2029298. PubMed ID: 35127252
[TBL] [Abstract] [Full Text] [Related]
5. MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells.
Hagiwara M; Fushimi A; Yamashita N; Bhattacharya A; Rajabi H; Long MD; Yasumizu Y; Oya M; Liu S; Kufe D
Oncogene; 2021 Jul; 40(30):4930-4940. PubMed ID: 34163028
[TBL] [Abstract] [Full Text] [Related]
6. Analysis of the concordance of 20 immunohistochemical tissue markers in metastasectomy lesions in patients with metastatic renal cell carcinoma: A retrospective study using tissue microarray.
Kim SH; Park WS; Park EY; Joo J; Chung J
Investig Clin Urol; 2020 Jul; 61(4):372-381. PubMed ID: 32665993
[TBL] [Abstract] [Full Text] [Related]
7. Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.
Bacon JVW; Annala M; Soleimani M; Lavoie JM; So A; Gleave ME; Fazli L; Wang G; Chi KN; Kollmannsberger CK; Wyatt AW; Nappi L
Clin Genitourin Cancer; 2020 Aug; 18(4):322-331.e2. PubMed ID: 32046920
[TBL] [Abstract] [Full Text] [Related]
8. New Insights into the Role of Polybromo-1 in prostate cancer.
Mota STS; Vecchi L; Zóia MAP; Oliveira FM; Alves DA; Dornelas BC; Bezerra SM; Andrade VP; Maia YCP; Neves AF; Goulart LR; Araújo TG
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31212728
[TBL] [Abstract] [Full Text] [Related]
9. The prognostic value of BAP1, pbrm1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry.
Kim SH; Park WS; Park EY; Park B; Joo J; Joung JY; Seo HK; Lee KH; Chung J
PLoS One; 2017; 12(6):e0179610. PubMed ID: 28654655
[TBL] [Abstract] [Full Text] [Related]
10. Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.
Tennenbaum DM; Manley BJ; Zabor E; Becerra MF; Carlo MI; Casuscelli J; Redzematovic A; Khan N; Arcila ME; Voss MH; Feldman DR; Motzer RJ; Benfante NE; Coleman JA; Russo P; Hsieh JJ; Hakimi AA
Urol Oncol; 2017 Aug; 35(8):532.e7-532.e13. PubMed ID: 28408295
[TBL] [Abstract] [Full Text] [Related]
11. Comprehensive Genomic Profiling of Renal Cell Carcinoma at Initial Diagnosis and Putative Local Recurrence.
Chalmers ZR; Johnson A; Ali SM; Frampton GM; Miller V; Ross JS; Pal SK
Eur Urol Focus; 2018 Mar; 4(2):267-269. PubMed ID: 28753749
[TBL] [Abstract] [Full Text] [Related]
12. Amino Acid Activation of mTORC1 by a pb1-Domain-Driven Kinase Complex Cascade.
Linares JF; Duran A; Reina-Campos M; Aza-Blanc P; Campos A; Moscat J; Diaz-Meco MT
Cell Rep; 2015 Aug; 12(8):1339-52. PubMed ID: 26279575
[TBL] [Abstract] [Full Text] [Related]
13. Somatic alterations contributing to metastasis of a castration-resistant prostate cancer.
Nickerson ML; Im KM; Misner KJ; Tan W; Lou H; Gold B; Wells DW; Bravo HC; Fredrikson KM; Harkins TT; Milos P; Zbar B; Linehan WM; Yeager M; Andresson T; Dean M; Bova GS
Hum Mutat; 2013 Sep; 34(9):1231-41. PubMed ID: 23636849
[TBL] [Abstract] [Full Text] [Related]
14. Of the atypical PKCs, Par-4 and p62: recent understandings of the biology and pathology of a pb1-dominated complex.
Moscat J; Diaz-Meco MT; Wooten MW
Cell Death Differ; 2009 Nov; 16(11):1426-37. PubMed ID: 19713972
[TBL] [Abstract] [Full Text] [Related]
15. Cytotoxic activity of Cuphea aequipetala.
Avila EV; Aguilar RT; Estrada MJ; Ortega ML; Ramos RR
Proc West Pharmacol Soc; 2004; 47():129-33. PubMed ID: 15633633
[TBL] [Abstract] [Full Text] [Related]
